Hims & Hers has been one of the most volatile stocks in the market.
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 13 Feb 2026, 17:00 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:24 UTC

AI-generated source summary
Hims & Hers (HIMS) stock has experienced significant volatility, declining over 25% recently after facing patent infringement lawsuits and FDA crackdowns on unapproved compounding. The company is set to report Q4 and full-year 2025 financial results on February 23, 2026. Despite the stock's recent drop, analysts suggest that HIMS's ability to grow its customer base and manufacturing capacity, coupled with its competitive pricing for weight-loss treatments, presents a potential buying opportunity. The company's forward P/E ratio has decreased to 31.89, its lowest point in the past year, indicating a more attractive valuation. Projections show substantial improvements in free cash flow and revenue growth over the next two years, with a target of $0.30 per share in free cash flow by Q4 2027, suggesting a strong underlying business despite current headwinds.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
